ReviewCells2020
Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer.
Review in Cells, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Early treatment outcome prediction in metastatic castration-resistant prostate cancer utilizing 3-month tumor growth rate (medRxiv : the preprint server for health sciences · 2026Article
- Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management.Current treatment options in oncology · 2024Review
- Neoadjuvant Androgen Receptor Signaling Inhibitors before Radical Prostatectomy for Non-Metastatic Advanced Prostate Cancer: A Systematic Review.Journal of personalized medicine · 2023Review
- Development and validation of a tumor immune cell infiltration-related gene signature for recurrence prediction by weighted gene co-expression network analysis in prostate cancer.Frontiers in genetics · 2023Article
- Androgen Metabolism and Response in Prostate Cancer Anti-Androgen Therapy Resistance.International journal of molecular sciences · 2022Review
- The Role of Histology-Agnostic Drugs in the Treatment of Metastatic Castration-Resistant Prostate Cancer.International journal of molecular sciences · 2022Review
- Beyond BRCA: The Emerging Significance of DNA Damage Response and Personalized Treatment in Pancreatic and Prostate Cancer Patients.International journal of molecular sciences · 2022Review
- Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer.Nature reviews. Urology · 2021Review
- Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse.Nature communications · 2021Article
- Preclinical Models in Prostate Cancer: Resistance to AR Targeting Therapies in Prostate Cancer.Cancers · 2021Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of targeted therapies increases treatment options for metastatic castration resistant prostate cancer (mCRPC) patients. There is a need for strong predictive and prognostic signatures to guide physicians in treating mCRPC patients. In this review we unravel the possible actionability in the AR pathway, PI3K AKT signaling, and DNA repair pathways. Additionally, we make recommendations on biomarker trial design, and the clinical use of this new type of data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.